Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs

Détails

ID Serval
serval:BIB_D70349D04E75
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs
Périodique
Immunol Rev
Auteur⸱e⸱s
Pesu M., Candotti F., Husa M., Hofmann S. R., Notarangelo L. D., O'Shea J. J.
ISSN
0105-2896 (Print)
ISSN-L
0105-2896
Statut éditorial
Publié
Date de publication
02/2005
Volume
203
Pages
127-42
Langue
anglais
Notes
Pesu, Marko
Candotti, Fabio
Husa, Matthew
Hofmann, Sigrun R
Notarangelo, Luigi D
O'Shea, John J
eng
Review
England
Immunol Rev. 2005 Feb;203:127-42.
Résumé
The recent elucidation of the multiple molecular mechanisms underlying severe combined immunodeficiency (SCID) is an impressive example of the power of molecular medicine. Analysis of patients and the concomitant generation of animal models mimicking these disorders have quickly provided great insights into the pathophysiology of these potentially devastating illnesses. In this review, we summarize the discoveries that led to the understanding of the role of cytokine receptors and a specific tyrosine kinase, Janus kinase 3 (Jak3), in the pathogenesis of SCID. We discuss how the identification of mutations of Jak3 in autosomal recessive SCID has facilitated the diagnosis of these disorders, offered new insights into the biology of this kinase, permitted new avenues for therapy, and provided the rationale for a generation of a new class of immunosuppressants.
Mots-clé
Humans, Immunosuppressive Agents/*pharmacology/therapeutic use, Janus Kinase 3, Mutation/genetics, Protein-Tyrosine Kinases/*antagonists & inhibitors/genetics/*physiology, Receptors, Cytokine/*genetics, Severe Combined Immunodeficiency/drug therapy/*genetics/immunology, Signal Transduction
Pubmed
Création de la notice
01/11/2017 10:29
Dernière modification de la notice
20/08/2019 15:56
Données d'usage